AcuraStem (acurastem.com), a patient-based company developing novel therapeutics for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases, announced the results of extensive preclinical studies on its lead program AS -202 for ALS patients. The data were presented on December 9 ...